Disrupting the vascular remodeling feedback signaling loop mediated by CD146-HIF-1α can effectively prevent the development of pulmonary hypertension (PH) in mice, a study found. This suggests that medicines that could target CD146-HIF-1α signals may represent a potential strategy to treat pulmonary arterial hypertension…
News
People who were born prematurely, especially in recent years, are more likely to develop pulmonary arterial hypertension (PAH) later in life, a study says. The findings of the study, “Increased risk of pulmonary hypertension following premature birth,” were published in the journal BMC Pediatrics. PAH is a rare,…
Blood levels of uric acid may be a predictive biomarker of pulmonary arterial hypertension (PAH) in people with scleroderma, according to a recent study. The levels of this normal body waste product, formed when chemicals called purines break down, also may be a biomarker for disease…
Imagine living your whole life with a painful disease so rare that only 25 others worldwide have what you have. And that you’re one of just six such people who’ve made it to adulthood. Neena Nizar doesn’t have to imagine. The 41-year-old English professor at Metro Community College in Elkhorn,…
Riociguat increases the risk of death and serious adverse events in people with pulmonary hypertension (PH) associated with idiopathic interstitial pneumonia (IIP), and should not be prescribed to those patients, final results of a Phase 2 study show. The study, “Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension…
A rise in the volume of red blood cells may help to identify people with chronic obstructive pulmonary disease who are at risk of also developing pulmonary hypertension, a study from China reports. It also may potentially serve as a a cost-effective biomarker for PH secondary…
Patients with group 2 pulmonary hypertension — those with PH due to left heart disease — show increased platelet respiration, which is associated with worse right ventricular function, according to new research. The study, “Alterations in platelet bioenergetics in Group 2 PH-HFpEF patients,” was published in…
A pulmonary hypertension (PH) patient has become the 1,000th recipient of a lung transplant at the University of Washington (UW) Medicine, the hospital recently announced. UW Medicine, the only institution in the Pacific Northwest that offers lung transplants, is the 11th in the United States to hit this…
The heart transplant program at the University of California San Diego Health has achieved the best one-year patient survival rate in the U.S., with surgeons working at the Cardiovascular Institute performing more than 50 heart transplants each year, data from the Scientific Registry of Transplant Recipients…
Blocking the protein interleukin-1 (IL-1) protects against pulmonary hypertension (PH) induced by complications from bronchopulmonary dysplasia (BPD) caused by high levels of oxygen, a new study in newborn mice reports. The findings have implications for the…
A Phase 2a trial testing the potential oral treatment rodatristat ethyl in patients with pulmonary arterial hypertension (PAH) has begun dosing, its developer announced. Rodatristat ethyl (or RVT-1201), the lead therapy candidate of Altavant Sciences, is an inhibitor of the enzyme tryptophan hydroxylase. The therapy is designed to…
Only a year ago, Florence Attaway — for decades a half-pack-a-day smoker — struggled to walk even one city block. “I had to take a taxi from my home one block to the hospital because I could hardly breathe,” said the 83-year-old New Yorker, who has chronic obstructive pulmonary…
